A new colorectal cancer drug has shocked researchers with how effective it is against the highly dangerous disease, as it virtually cured it in every member of a clinical trial.Dostarlimab, a monoclonal antibody drug, smashed expectations in a recent trial sponsored by pharma giant GlaxoSmithKline (GSK).A year after the trial's completion, each of the 18 participants had their disease go into complete remission, with doctors unable to find signs of the cancer in their body.
Load More
Load More